Boys receive free protection; boys do not.
Across South Africa, a preventable virus quietly claims men's health — in their throats, their fertility, their futures — while a national vaccination program looks the other way. HPV, one of the most common infections in human history, is understood well enough to be stopped, yet the country's public health strategy protects only girls, leaving boys to navigate a danger they were never warned about. The logic of herd immunity, appealing in theory, has proven insufficient in practice, and the gap between what science recommends and what policy delivers grows wider each year. Other African nations are beginning to close this divide; South Africa has yet to follow.
- Men are being diagnosed with HPV-driven throat, penile, and anal cancers late — often after years of no screening, no warning, and no vaccine — making treatment harder and survival less certain.
- The government's free HPV vaccination program covers girls aged nine to fourteen but excludes boys entirely, embedding a health inequity into national policy that leaves half the population undefended.
- Private vaccination costs between R1,102 and R2,365 per dose with little medical aid coverage, pricing protection out of reach for most South African families and deepening the divide along economic lines.
- The herd immunity strategy underpinning the girls-only approach has measurable gaps — not everyone gets vaccinated, viruses mutate, and immunity wanes — meaning boys remain genuinely exposed, not passively protected.
- Mauritius, Eswatini, and Cameroon are moving toward gender-neutral HPV vaccination, while global research shows vaccinating both sexes achieves full population protection in eight years rather than twenty.
- Experts and advocates are calling on South Africa to honour its National Health Insurance commitments by expanding the free program to boys before another generation of preventable cancers takes hold.
A man in his forties sits across from his doctor with a lump in his throat. He doesn't smoke, doesn't drink heavily, has no family history of cancer. What he has is HPV — a virus so common that most people encounter it in their lifetimes, yet one he was never tested for, never warned about, and never vaccinated against. This scene repeats itself in consulting rooms across South Africa with quiet regularity.
HPV spreads through sexual contact and skin-to-skin intimacy. Condoms offer only partial protection. Most infections clear on their own, but when the virus persists, it becomes dangerous — causing cancers of the penis, anus, and throat in men, as well as reducing fertility and potentially contributing to prostate cancer. Globally, one in five men carries a cancer-causing HPV strain, and these cancers are rising, particularly among unvaccinated males.
South Africa's 2026–2030 health strategy commits to free HPV vaccination for girls aged nine to fourteen in public and private schools — sound policy, given that HPV causes 95 percent of cervical cancers. But boys are excluded entirely. The government's reasoning rests on herd immunity: protect enough girls and boys benefit indirectly. In practice, this logic has limits. Vaccination coverage is never total, viruses mutate, and immunity fades. Men are left without a defence against cancers that are entirely preventable.
No routine HPV-related screening exists for men in South Africa's public health system. Women over thirty can access free cervical cancer screening; men have no equivalent. The result is that male cancers are caught late, treated harder, and more often fatal. For men living with HIV, the risk is steeper still — weakened immunity allows HPV to persist and recur.
For boys who want protection, the private sector charges between R1,102 and R2,365 per dose, with most medical aid schemes declining to cover it. The message embedded in this arrangement, whether intentional or not, is that men's health is a lower priority. Yet the evidence for gender-neutral vaccination is robust: one study found vaccinating fourteen-year-old boys could prevent over 416,000 cancer cases, and vaccinating both sexes achieves in eight years the protection that takes twenty when only girls are covered.
Mauritius has already begun a gender-neutral approach. Eswatini plans to follow in late 2026. Cameroon is advancing in the same direction. South Africa, which has committed through its National Health Insurance Act to universal healthcare regardless of ability to pay, has yet to act. The short-term cost of expanding vaccination to boys is modest. The long-term cost — in advanced cancers, lost lives, and broken families — is far greater.
A man in his forties sits across from his doctor with a lump in his throat. He doesn't smoke. He doesn't drink much. Cancer doesn't run in his family. What he has instead is a virus so common that most people encounter it at some point in their lives, yet he's never been tested for it, never heard a warning about it, and certainly never imagined it could kill him. This scene plays out in doctor's offices across South Africa and around the world with troubling regularity.
The virus is human papillomavirus, or HPV. It spreads through sexual contact—vaginal, oral, anal—and through skin-to-skin intimacy. Condoms offer incomplete protection because HPV can infect areas they don't cover: the scrotum, vulva, perineum, anus, upper thighs. Most people who contract it clear the infection naturally within a year or two. But when it persists, it becomes dangerous. Globally, about one in three men carries at least one genital HPV type. One in five carries a type that causes cancer. These cancers emerge in the penis, anus, and throat—and they're rising worldwide, particularly in unvaccinated men.
South Africa has recognized HPV as a public health threat, but only half the population. The country's 2026-2030 health strategy commits to vaccinating girls from age nine through fourteen against HPV, free of charge, in both public and private schools. This is sound policy. HPV causes 95 percent of cervical cancers, and the vaccination program will save lives. But the strategy stops there. Boys are excluded entirely from the government's free vaccination program. The assumption underlying this choice is that vaccinating girls will indirectly protect boys through herd immunity—if enough people are protected, the virus loses its foothold. The logic is appealing. The problem is it doesn't work completely. Not everyone gets vaccinated. Viruses mutate. Protection weakens over time. And it leaves an entire population undefended against cancers that are entirely preventable.
For men in South Africa, HPV-related cancers are often discovered late because no routine screening exists in the public healthcare system. Women aged thirty and older can access free cervical cancer screening every ten years at government clinics. Those living with HIV can be screened every three years, recognizing their higher vulnerability. Men have no equivalent. Some doctors may recommend anal pap smears for men who have receptive anal sex, but this is neither routine nor widely available. The result is that men face cancers that are harder to treat because they're caught later. In the United States and other wealthy countries, HPV-driven throat cancers in men now outnumber cervical cancers in women—a shift driven largely by vaccination gaps in males. The risk is even steeper for men with HIV, whose weakened immune systems allow HPV infections to persist and recur.
Beyond cancer, HPV damages men in ways that rarely make headlines. Research shows the virus can reduce fertility by harming sperm, complicating family planning. Evidence is mounting that HPV contributes to prostate cancer, a disease expected to surge by nearly 65 percent globally between 2020 and 2040. Yet boys and men remain largely absent from vaccination programs, partly because the World Health Organization's guidance prioritizes vaccinating girls aged nine to fourteen, with vaccination of males and older women recommended only when feasible and affordable—a caveat that has allowed countries to defer indefinitely.
In South Africa, boys who want HPV protection must turn to the private sector, where a single dose costs between R1,102 and R2,365, depending on which of three available vaccines they choose and how many doses the regimen requires. Most medical aid schemes don't cover it. For families without substantial means, the vaccine is simply out of reach. This creates a stark inequity: girls receive free protection; boys do not. The message, whether intended or not, is that protecting men's health matters less.
Yet the evidence for vaccinating both genders is overwhelming. Research from countries like China demonstrates that vaccinating fourteen-year-old boys is not only effective but cost-effective—one study found it could prevent over 416,000 cancer cases. Vaccinating both boys and girls achieves in eight years the same level of protection that takes twenty years when only girls are vaccinated. Several African nations have already begun moving toward gender-neutral approaches. Mauritius has started. Eswatini plans to begin in late 2026. Cameroon is advancing in this direction. Wealthy countries across the globe have adopted gender-neutral vaccination strategies, and the UN General Assembly has backed the inclusion of boys in HPV programs worldwide.
South Africa has committed through the National Health Insurance Act to provide everyone access to the same healthcare regardless of ability to pay. That promise rings hollow if preventable diseases are allowed to ravage half the population. The short-term cost of expanding vaccination to boys is real but modest. The long-term cost of treating advanced cancers, lost income, and preventable deaths is far steeper. The time to act is now.
Citações Notáveis
HPV is not just a women's issue. It is a men's health issue, too—one that is often silent, but potentially life-threatening.— Damian Naidoo, Kaymarlin Govender, and Joanne E Mantell, public health researchers
A Conversa do Hearth Outra perspectiva sobre a história
Why has South Africa focused only on girls when HPV affects both sexes?
The strategy assumes vaccinating girls will protect boys indirectly through herd immunity—fewer infected women means less virus circulating. It's a reasonable starting point, but it has real gaps. Not everyone gets vaccinated, viruses mutate, and protection fades. You're essentially betting on a shield that isn't complete.
What happens to men who get HPV in South Africa right now?
Most don't know they have it. There's no routine screening for men in the public sector, unlike the free cervical cancer screening women receive. So cancers are often found late, when they're harder to treat. A man might walk into his doctor's office with a lump in his throat and have no idea why it's there.
Is HPV vaccination expensive to add to the program?
Not prohibitively. The real cost is the long-term burden of treating cancer, lost productivity, and preventable deaths. But yes, in the short term, it requires budget allocation. That's where the equity question becomes urgent—girls get it free, boys have to pay R1,100 to R2,300 per shot privately. Most families can't afford that.
Other countries have solved this. What are they doing?
Many wealthy nations now vaccinate both boys and girls. Some African countries like Mauritius and Eswatini are following suit. The research is clear: vaccinating both genders cuts the time to achieve full protection from twenty years down to eight. It's not experimental. It works.
What's the human cost of leaving boys out?
Cancer that could have been prevented. Reduced fertility affecting family planning. Men discovering late-stage disease when treatment is brutal and outcomes are worse. And a message that their health is less important than girls'. That's a cost too.
What would change if South Africa expanded the program?
You'd protect an entire generation of men from cancers of the throat, anus, and penis. You'd reduce HPV circulation across the whole population faster. And you'd honor the commitment to equitable healthcare that South Africa has already made in law.